BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20007294)

  • 1. Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs.
    Mills BM; Zaya MJ; Walters RR; Feenstra KL; White JA; Gagne J; Locuson CW
    Drug Metab Dispos; 2010 Mar; 38(3):396-404. PubMed ID: 20007294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro drug-drug interaction screens for canine veterinary medicines: evaluation of cytochrome P450 reversible inhibition.
    Aidasani D; Zaya MJ; Malpas PB; Locuson CW
    Drug Metab Dispos; 2008 Aug; 36(8):1512-8. PubMed ID: 18448570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
    Lu C; Balani SK; Qian MG; Prakash SR; Ducray PS; von Moltke LL
    J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.
    Stringer RA; Strain-Damerell C; Nicklin P; Houston JB
    Drug Metab Dispos; 2009 May; 37(5):1025-34. PubMed ID: 19196847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.
    Desta Z; Soukhova N; Mahal SK; Flockhart DA
    Drug Metab Dispos; 2000 Jul; 28(7):789-800. PubMed ID: 10859153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
    Obach RS; Walsky RL; Venkatakrishnan K; Gaman EA; Houston JB; Tremaine LM
    J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.
    Lu C; Miwa GT; Prakash SR; Gan LS; Balani SK
    Drug Metab Dispos; 2007 Jan; 35(1):79-85. PubMed ID: 17020957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Escherichia coli membrane preparations of canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with coexpressed canine cytochrome P450 reductase.
    Locuson CW; Ethell BT; Voice M; Lee D; Feenstra KL
    Drug Metab Dispos; 2009 Mar; 37(3):457-61. PubMed ID: 19074522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions.
    McGinnity DF; Waters NJ; Tucker J; Riley RJ
    Drug Metab Dispos; 2008 Jun; 36(6):1126-34. PubMed ID: 18356267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450.
    Chen Y; Liu L; Nguyen K; Fretland AJ
    Drug Metab Dispos; 2011 Mar; 39(3):373-82. PubMed ID: 21148079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.
    Lu C; Hatsis P; Berg C; Lee FW; Balani SK
    Drug Metab Dispos; 2008 Jul; 36(7):1255-60. PubMed ID: 18381489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of different approaches to predict metabolic drug-drug interactions.
    Einolf HJ
    Xenobiotica; 2007; 37(10-11):1257-94. PubMed ID: 17968745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
    Prueksaritanont T; Gorham LM; Ma B; Liu L; Yu X; Zhao JJ; Slaughter DE; Arison BH; Vyas KP
    Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
    Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
    Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments.
    Komatsu K; Ito K; Nakajima Y; Kanamitsu Si; Imaoka S; Funae Y; Green CE; Tyson CA; Shimada N; Sugiyama Y
    Drug Metab Dispos; 2000 Apr; 28(4):475-81. PubMed ID: 10725317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes.
    Iwatsubo T; Suzuki H; Shimada N; Chiba K; Ishizaki T; Green CE; Tyson CA; Yokoi T; Kamataki T; Sugiyama Y
    J Pharmacol Exp Ther; 1997 Aug; 282(2):909-19. PubMed ID: 9262358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination.
    Brown HS; Chadwick A; Houston JB
    Drug Metab Dispos; 2007 Nov; 35(11):2119-26. PubMed ID: 17724064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
    Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
    Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.